Immunodeficiency Clinical Trials

108 recruitingLast updated: June 18, 2026

There are 108 actively recruiting immunodeficiency clinical trials across 47 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Bethesda, Maryland, United States, Baltimore, Maryland, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Immunodeficiency Trials at a Glance

108 actively recruiting trials for immunodeficiency are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Not Applicable with 27 trials, with the heaviest enrollment activity in Bethesda, Baltimore, and San Francisco. Lead sponsors running immunodeficiency studies include National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and Merck Sharp & Dohme LLC.

Browse immunodeficiency trials by phase

Treatments under study

About Immunodeficiency Clinical Trials

Looking for clinical trials for Immunodeficiency? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunodeficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunodeficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 108 trials

Recruiting

Genetic Basis of Immunodeficiency

Severe Combined Immunodeficiency
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT00055172
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting

The Mechanistic Biology of Primary Immunodeficiency Disorders

Primary Immunodeficiency Disorders
National Institute of Allergy and Infectious Diseases (NIAID)2,500 enrolled2 locationsNCT03394053
Recruiting
Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

Human Immunodeficiency Virus (HIV) -1 infectionHIV-1 Subtype A6 InfectionHIV-1 Subtype B Infection+1 more
Pomeranian Medical University Szczecin250 enrolled7 locationsNCT07370649
Recruiting
Phase 2

Boosting Olfactory and Sensory Training Study (BOOST)

HIV (Human Immunodeficiency Virus)
University of Alabama at Birmingham80 enrolled1 locationNCT07221123
Recruiting

NIAID Centralized Sequencing Protocol

autoimmunityPrimary ImmunodeficiencyAtopy+1 more
National Institute of Allergy and Infectious Diseases (NIAID)20,000 enrolled2 locationsNCT03206099
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled81 locationsNCT07044297
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled56 locationsNCT07266831
Recruiting
Phase 1Phase 2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting

Genetic Analysis of Immune Disorders

ImmunodeficiencyGATA2DOK 8+2 more
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled1 locationNCT00001467
Recruiting
Not Applicable

Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection

Alcohol Use DisorderHuman Immunodeficiency Virus
Rush University Medical Center40 enrolled1 locationNCT06139224
Recruiting
Not Applicable

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical CancerHuman Papillomavirus (HPV) InfectionHuman Immunodeficiency Virus (HIV) Infection
University of California, Irvine348 enrolled3 locationsNCT07209917
Recruiting
Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled30 locationsNCT07071623
Recruiting
Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting

BRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS

CancerChronic Kidney DiseaseCardiovascular and Cerebrovascular Diseases+2 more
Hospital Alemão Oswaldo Cruz743 enrolled9 locationsNCT07118683
Recruiting
Phase 3

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Multiple MyelomaSecondary Immunodeficiency
Takeda183 enrolled28 locationsNCT06980480
Recruiting
Not Applicable

HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
University of Washington30,000 enrolled1 locationNCT07089966